tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Dermatomycoses D003881 17 associated lipids
Dermatomyositis D003882 2 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Digestive System Diseases D004066 3 associated lipids
Down Syndrome D004314 18 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Dyspnea D004417 10 associated lipids
Earache D004433 2 associated lipids
Echinostomiasis D004451 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Eczema D004485 4 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Epididymitis D004823 1 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Erythema D004890 22 associated lipids
Erythema Nodosum D004893 5 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Erythroplasia D004919 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Exanthema D005076 11 associated lipids
Eye Diseases D005128 12 associated lipids
Facial Dermatoses D005148 7 associated lipids
Facial Neoplasms D005153 3 associated lipids
Fatigue D005221 10 associated lipids
Fatty Liver D005234 48 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Folliculitis D005499 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Foot Dermatoses D005533 3 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hattori Y et al. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus. 2014 Transplant. Proc. pmid:24656015
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Wang XH et al. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation. 2000 Transplant. Proc. pmid:11119899
Jordan ML et al. FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. 1993 Transplant. Proc. pmid:7679827
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Jusko WJ and D'Ambrosio R Monitoring FK 506 concentrations in plasma and whole blood. 1991 Transplant. Proc. pmid:1721260
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Millis JM et al. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. 1996 Transplant. Proc. pmid:8623213
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Staschak S et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. 1990 Transplant. Proc. pmid:1689896
Aravot D et al. A new immunosuppressive protocol for lung transplantation: early promising results. 2003 Transplant. Proc. pmid:12644072
Molleví DG et al. Late xenograft rejection: comparison between liver and heart xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959212
Weiler N et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? 2013 Jul-Aug Transplant. Proc. pmid:23953543
Cai TH et al. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636572
Pascual J et al. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. 2005 Transplant. Proc. pmid:16386525
Lo CM et al. More effective immunosuppression with the use of FK506 after liver transplantation. 2000 Transplant. Proc. pmid:11120161
van Hooff JP et al. Dosing and management guidelines for tacrolimus in renal transplant patients. 1999 Transplant. Proc. pmid:10576046
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Klintmalm GB Clinical use of FK 506 in liver transplantation. 1996 Transplant. Proc. pmid:8623484
Merli M et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. 2010 Transplant. Proc. pmid:20534292
Goulet O et al. Small bowel transplantation alone or with the liver in children: changes by using FK506. 1998 Transplant. Proc. pmid:9636636
Vincenti F et al. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. 2005 Transplant. Proc. pmid:15848604
Gerber DA et al. Immunosuppressive agents: recent developments in molecular action and clinical application. 1998 Transplant. Proc. pmid:9636637
DemirbaÅŸ A et al. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients. 2004 Jan-Feb Transplant. Proc. pmid:15013338
Fan Y et al. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. 2009 Transplant. Proc. pmid:19545736
Spagnoletti G et al. Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up. 2014 Transplant. Proc. pmid:25242756
Gozdowska J et al. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience. 2011 Transplant. Proc. pmid:21996197
Kliem V et al. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. 1997 Transplant. Proc. pmid:9365627
Xu M et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation. 1997 Transplant. Proc. pmid:9365631
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Ziolkowski J et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. 2003 Transplant. Proc. pmid:14529923
Yasunami Y et al. Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. 1992 Transplant. Proc. pmid:1376510
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Ushigome H et al. Pediatric living-related renal transplantation under tacrolimus as the primary immunosuppressive agent. 2003 Transplant. Proc. pmid:12591350
Costa JS et al. Polyomavirus Nephropathy: Ten-Year Experience. 2017 Transplant. Proc. pmid:28457399
Motta I et al. FK 506 favors the generation of memory T cells in vitro. 1991 Transplant. Proc. pmid:1721324
Isai H et al. FK 506 and orthotopic liver transplantation in the rat. 1990 Transplant. Proc. pmid:1699329
Daly I et al. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. 2002 Transplant. Proc. pmid:12176458
Hasegawa A et al. Successful treatment of 115 pediatric renal transplant recipients with tacrolimus-based immunosuppressive therapy: a 7-year multicenter study in Japan. 2005 Transplant. Proc. pmid:15919460
Hasegawa A et al. Improvement of quality of life in tacrolimus-based pediatric renal transplant recipients and their caregivers, including donors. 2005 Transplant. Proc. pmid:15919461
Viganò J et al. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series. 2008 Jul-Aug Transplant. Proc. pmid:18675099
Cakir U et al. Role of Everolimus on Cardiac Functions in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28340820
Esposito C et al. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. 2004 Transplant. Proc. pmid:15110634
Orlandi V et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. 2004 Transplant. Proc. pmid:15110639
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
Pape L et al. Long-term stable glomerular filtration rate achieved with tacrolimus in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12270367
Fischereder M et al. Gynaecomastia following solid organ transplantation. 2002 Transplant. Proc. pmid:12270376
Rodrigues N et al. Serum Magnesium and Related Factors in Long-Term Renal Transplant Recipients: An Observational Study. 2017 Transplant. Proc. pmid:28457398
Budde K et al. Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 2002 Transplant. Proc. pmid:12176499
Park CS et al. Tetrahydrocurcumin Ameliorates Tacrolimus-Induced Nephrotoxicity Via Inhibiting Apoptosis. 2018 Transplant. Proc. pmid:30401411
Jabiry-Zieniewicz Z et al. Outcome of four high-risk pregnancies in female liver transplant recipients on tacrolimus immunosuppression. 2006 Jan-Feb Transplant. Proc. pmid:16504718
Shu KH et al. A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. 1998 Transplant. Proc. pmid:9838570
Bennett WM Renal complications after heart transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083019
Ko S et al. Predominant role of local immunosuppressive effect in enhanced efficacy of liposomal FK506 in organ transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123117
Rao AS et al. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. 1996 Transplant. Proc. pmid:8908140
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Schwarz C et al. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis. 2015 Transplant. Proc. pmid:26518948
Townamchai N et al. A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period. 2015 Transplant. Proc. pmid:26518946
Baran DA et al. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. 2002 Transplant. Proc. pmid:12176547
Jordán de Luna C et al. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. 2011 Jul-Aug Transplant. Proc. pmid:21839244
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 1999 Feb-Mar Transplant. Proc. pmid:10083507
Batten P et al. Effect of cyclosporine A and FK 506 on human T cell responses to xenogeneic and allogeneic endothelium: relative resistance of T cell/porcine endothelial interactions. 1997 Feb-Mar Transplant. Proc. pmid:9123582
Troppmann C et al. FK 506 versus cyclosporine A for steroid-free synergistic combination therapy with rapamycin in a discordant large animal donor xenoislet transplant model. 1997 Feb-Mar Transplant. Proc. pmid:9123585
Adibelli Z et al. An unusual presentation of sirolimus associated cough in a renal transplant recipient. 2007 Transplant. Proc. pmid:18089408
Htun YY et al. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. 2018 Transplant. Proc. pmid:29731062
Braun N et al. Impairment of renal function following liver transplantation. 2003 Transplant. Proc. pmid:12826191
Markus PM et al. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721418
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
Cooper MH et al. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. 1991 Transplant. Proc. pmid:1721419
Yagura K et al. Pharmacokinetic characteristics of two types of liposomal FK 506. 1996 Transplant. Proc. pmid:8658708
Taber DJ et al. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. 2000 Transplant. Proc. pmid:10812156
El-Sabrout R et al. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience. 2003 Transplant. Proc. pmid:12742474
Filler G et al. One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. 2002 Transplant. Proc. pmid:12176634
Glanemann M et al. Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267194
Ueno T et al. Conversion to prolonged-release tacrolimus for pediatric living related donor liver transplant recipients. 2013 Transplant. Proc. pmid:23769087
Fuchs U et al. Clinical outcome in cardiac transplant recipients receiving tacrolimus retard. 2013 Transplant. Proc. pmid:23769094
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Alessiani M et al. Effect of perioperative donor bone marrow infusion after small bowel transplantation in swine: preliminary results. 1998 Transplant. Proc. pmid:9745496
Ybarra J et al. Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus. 2003 Transplant. Proc. pmid:14697943
Cintra-Cabrera M et al. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review. 2018 Transplant. Proc. pmid:29579856
Yumiba T et al. Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. 1995 Transplant. Proc. pmid:7540780
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Ochiai T et al. Studies on FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450414
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
Back JH et al. Antiproteinuric Effects of Green Tea Extract on Tacrolimus-Induced Nephrotoxicity in Mice. Transplant. Proc. pmid:26293093
Mehra MR et al. A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267438
Mehra MR et al. Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267442
Shi G et al. Variation of CD4CD25Foxp3 Regulatory T Cells and Th17 Cells in the Peripheral Blood of Human Liver Allograft Patients With Long-term Survival. 2017 Transplant. Proc. pmid:28923634
Yura H et al. Development of a macromolecular prodrug of FK 506: II: In vitro study for FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636416
Duzova A et al. Triple immunosuppression with tacrolimus in pediatric renal transplantation: single-center experience. 2008 Jan-Feb Transplant. Proc. pmid:18261567
Wu J et al. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. 1991 Transplant. Proc. pmid:1703683
Han SY et al. Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells. 2006 Transplant. Proc. pmid:16980053
Han SY et al. Effect of tacrolimus on the production of oxygen free radicals in hepatic mitochondria. 2006 Transplant. Proc. pmid:16980054
Boggi U et al. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750373
Copley JB et al. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. 1998 Transplant. Proc. pmid:9636510